Literature DB >> 27464481

Rheumatoid arthritis: Tocilizumab and the risk of intestinal perforation.

Lydia Shipman.   

Abstract

Entities:  

Year:  2016        PMID： 27464481     DOI： 10.1038/nrrheum.2016.130

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN： 1759-4790            Impact factor:   20.543


× No keyword cloud information.
  1 in total

1.  Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDs.

Authors:  A Strangfeld; A Richter; B Siegmund; P Herzer; K Rockwitz; W Demary; M Aringer; Y Meißner; A Zink; J Listing
Journal:  Ann Rheum Dis       Date:  2016-07-12       Impact factor: 19.103
  1 in total
  3 in total

1.  Follow the complex bread crumbs: A review of autoinflammation for the general paediatrician.

Authors:  Paul Tsoukas; Ronald M Laxer
Journal:  Paediatr Child Health       Date:  2019-07-18       Impact factor: 2.253

Review 2.  The Innate and Adaptive Immune System as Targets for Biologic Therapies in Inflammatory Bowel Disease.

Authors:  Grainne Holleran; Loris Lopetuso; Valentina Petito; Cristina Graziani; Gianluca Ianiro; Deirdre McNamara; Antonio Gasbarrini; Franco Scaldaferri
Journal:  Int J Mol Sci       Date:  2017-09-21       Impact factor: 5.923

Review 3.  Cellular and Molecular Therapeutic Targets in Inflammatory Bowel Disease-Focusing on Intestinal Barrier Function.

Authors:  Ida Schoultz; Åsa V Keita
Journal:  Cells       Date:  2019-02-22       Impact factor: 6.600
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.